Arvinas is a biotechnology company developing protein degradation therapies using PROTAC technology, which works by leveraging the body's natural cellular disposal mechanisms to eliminate disease-causing proteins. The company's pipeline includes candidates targeting neurodegenerative diseases like Parkinson's, various cancers including those with specific genetic mutations, non-Hodgkin lymphoma, and hormone-driven cancers such as breast and prostate cancer. Arvinas collaborates with major pharmaceutical partners including Pfizer, Genentech, Roche, and Bayer on these drug development programs.
1Y: 7.86 (-22.5%) · range 6.82–13.83
entry readiness 51 · MODERATE · exit proximity 0
Value area 7.60–9.33 · 70% of 120d volume overhead · heavy supply
No source detections in the last 21 days.
| Horizon | Return | MFE | State |
|---|---|---|---|
| 20d | -6.22% | +7.44% | mature |
| 40d | -15.21% | +7.44% | mature |